Wallace L. Akerley
( out of 209 reviews )

Wallace L. Akerley, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Clinic 1A, Thoracic
Salt Lake City
801-213-4266

  • Wallace Akerley, MD is a medical oncologist with greater than 30 years experience as a principal investigator on numerous clinical research trials who actively cares for patients with lung cancer. He is the chairman of the Protocol Review and Monitoring Committee at Huntsman Cancer Institute (HCI), Director of the Lung Cancer Disease Center of Excellence at HCI and member of the NCCN's Steering Committee for Small Cell Lung Cancer Panel and NSCLC Panel.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)
    National Board of Medical Examiners

    Patient Rating

    5.0 /5
    ( out of 209 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    March 31, 2025
    HUNTSMAN CANCER CENTER

    An exceptional Doctor!!!

    March 28, 2025
    HUNTSMAN CANCER CENTER

    I'm sad that Dr akerley won't be around for my entire journey but happy for him to slow down a bit

    March 23, 2025
    HUNTSMAN CANCER CENTER

    Very kind, professional and seasoned

    March 14, 2025
    HUNTSMAN CANCER CENTER

    VERY KIND

    March 01, 2025
    HUNTSMAN CANCER CENTER

    Dr. Akerley is great to work with. He is interested, kind and knowledgeable. I have been fighting cancer for almost five years and he has helped me to stay alive.

    February 15, 2025
    HUNTSMAN CANCER CENTER

    On first meeting very impressed and thankful to have Dr Akerley leading my team.

    February 13, 2025
    HUNTSMAN CANCER CENTER

    Dr Akerley I truly an earthly angel! I couldn't love him more than I do! His eyes radiate warmth and concern. He is deeply personal and deeply kind. You walk away from him smiling, because you just engaged with the kindest man on earth. My husband and I adore him and are so grateful for his loving personality and his depth of knowledge. What a man!!

    January 25, 2025
    HUNTSMAN CANCER CENTER

    Doc Akerley the best

    January 16, 2025
    HUNTSMAN CANCER CENTER

    Dr. Wallace L. Akerley's medical professional knowledges are excellence.

    See More Patient Comments

  • Wallace Akerley, MD is a medical oncologist with greater than 30 years experience as a principal investigator on numerous clinical research trials who actively cares for patients with lung cancer. He is the chairman of the Protocol Review and Monitoring Committee at Huntsman Cancer Institute (HCI), Director of the Lung Cancer Disease Center of Excellence at HCI and member of the NCCN's Steering Committee for Small Cell Lung Cancer Panel and NSCLC Panel.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Professor
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)
    National Board of Medical Examiners

    Education history

    Fellowship Hematology/Oncology - Dartmouth Hitchcock Medical Ctr. Fellow
    Fellowship Oncology - University of Southern California Fellow
    Internship Internal Medicine - University of Southern California Intern
    Residency Internal Medicine - University of Southern California Resident
    Professional Medical Medicine - Brown University M.D.
    Undergraduate Engineering - Boston University B.S.

    Selected Publications

    Journal Article

    1. Jo Y, Puri S, Haaland B, Coletta AM, Chipman JJ, Embrey K, Kerrigan KC, Patel SB, Moynahan K, Gumbleton M, Akerley WL (2024). Augmenting Prognostication: Utilizing Activity Trackers to Enhance Survival Prediction in Metastatic Non-Small Cell Lung Cancer. Clin Lung Cancer, 26(1), 29-38. (Read full article)
    2. Mitzman B, Varghese TK Jr, Akerley WL, Nelson RE (2024). Surgical-decision making in the setting of unsuspected N2 disease: a cost-effectiveness analysis. J Thorac Dis, 16(2), 1063-1073. (Read full article)
    3. Amann ES, Ose J, Hathaway CA, Oswald LB, Hardikar S, Himbert C, Chellam V, Lin T, Daniels B, Kirchhoff AC, Gigic B, Grossman D, Tward J, Varghese TK Jr, Shibata D, Figueiredo JC, Toriola AT, Beck A, Scaife C, Barnes CA, Matsen C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Grady WM, Schneider M, Dinkel A, Islam JY, Gonzalez BD, Otto AK, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples AR (2024). Risk factors and health behaviors associated with loneliness among cancer survivors during the COVID-19 pandemic. J Behav Med, 47(3), 405-421. (Read full article)
    4. McCarty RD, Barnard ME, Lawson-Michod KA, Owens M, Green SE, Derzon S, Karabegovic L, Akerley WL, Watt MH, Doherty JA, Grieshober L (2023). Pathways to lung cancer diagnosis among individuals who did not receive lung cancer screening: a qualitative study. BMC Prim Care, 24(1), 203. (Read full article)
    5. Gadgeel SM, Miao J, Riess JW, Moon J, Mack PC, Gerstner GJ, Burns TF, Taj A, Akerley WL, Dragnev KH, Laudi N, Redman MW, Gray JE, Gandara DR, Kelly K (2023). Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042). Clin Cancer Res. (Read full article)
    6. Rudin CM, Pandha HS, Zibelman M, Akerley WL, Harrington KJ, Day D, Hill AG, ODay SJ, Clay TD, Wright GM, Jennens RR, Gerber DE, Rosenberg JE, Ralph C, Campbell DC, Curti BD, Merchan JR, Ren Y, Schmidt EV, Guttman L, Gupta S (2022). Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. J Immunother Cancer, 11(1). (Read full article)
    7. Morris BB, Smith JP, Zhang Q, Jiang Z, Hampton OA, Churchman ML, Arnold SM, Owen DH, Gray JE, Dillon PM, Soliman HH, Stover DG, Colman H, Chakravarti A, Shain KH, Silva AS, Villano JL, Vogelbaum MA, Borges VF, Akerley WL, Gentzler RD, Hall RD, Matsen CB, Ulrich CM, Post AR, Nix DA, Singer EA, Larner JM, Stukenberg PT, Jones DR, Mayo MW (2022). Replicative Instability Drives Cancer Progression. Biomolecules, 12(11). (Read full article)
    8. Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples AR (2022). Factors associated with changes in exercise behaviors during the COVID-19 pandemic. Cancer Causes Control, 33(7), 939-950. (Read full article)
    9. Peoples AR, Oswald LB, Ose J, Daniels B, Himbert C, Hathaway CA, Gigic B, Kirchhoff AC, Lin T, Grossman D, Tward J, Varghese TK Jr, Figueiredo JC, Toriola AT, Beck A, Scaife C, Shibata D, LaStayo P, Gonzalez B, Salas K, Ashworth A, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM (2022). Impact of the COVID-19 pandemic on rural and urban cancer patients' experiences, health behaviors, and perceptions. J Rural Health, 38(4), 886-899. (Read full article)
    10. Rich P, Mitchell RB, Schaefer E, Walker PR, Dubay JW, Boyd J, Oubre D, Page R, Khalil M, Sinha S, Boniol S, Halawani H, Santos ES, Brenner W, Orsini JM, Pauli E, Goldberg J, Veatch A, Haut M, Ghabach B, Bidyasar S, Quejada M, Khan W, Huang K, Traylor L, Akerley W (2021). Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer. J Immunother Cancer, 9(10). (Read full article)
    11. Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami PJ (2021). A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer, 21(1), 510. (Read full article)
    12. Morris BB, Wages NA, Grant PA, Stukenberg PT, Gentzler RD, Hall RD, Akerley WL, Varghese TK, Arnold SM, Williams TM, Coppola V, Jones DR, Auble DT, Mayo MW (2021). MYBL2-Driven Transcriptional Programs Link Replication Stress and Error-prone DNA Repair With Genomic Instability in Lung Adenocarcinoma. Front Oncol, 10, 585551. (Read full article)
    13. Chalmers AW, Patel S, Boucher K, Cannon L, Esplin M, Luckart J, Graves N, Van Duren T, Akerley W (2019). Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up. Target Oncol, 14(4), 417-421. (Read full article)
    14. Chalmers A, Cannon L, Akerley W (2018). Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib. Oncologist, 24(7), 963-972. (Read full article)
    15. Cannon-Albright LA, Carr SR, Akerley W (2019). Population-Based Relative Risks for Lung Cancer Based on Complete Family History of Lung Cancer. J Thorac Oncol, 14(7), 1184-1191. (Read full article)
    16. Buttigliero C, Shepherd FA, Barlesi F, Schwartz B, Orlov S, Favaretto AG, Santoro A, Hirsh V, Ramlau R, Blackler AR, Roder J, Spigel D, Novello S, Akerley W, Scagliotti GV (2018). Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. Oncologist, 24(6), e251-e259. (Read full article)
    17. Kalemkerian GP, Loo BW, Akerley W, Attia A, Bassetti M, Boumber Y, Decker R, Dobelbower MC, Dowlati A, Downey RJ, Florsheim C, Ganti AKP, Grecula JC, Gubens MA, Hann CL, Hayman JA, Heist RS, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran CA, Morgensztern D, Pokharel S, Portnoy DC, Rhodes D, Rusthoven C, Santana-Davila R, Williams CC, Hoffmann KG, Hughes M (2018). NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. J Natl Compr Canc Netw, 16(10), 1171-1182. (Read full article)
    18. Carr SR, Akerley W, Cannon-Albright LA (2018). Genetic Contribution to Nonsquamous, Non-Small Cell Lung Cancer in Nonsmokers. J Thorac Oncol, 13(7), 938-945. (Read full article)
    19. Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, Chirieac LR, DAmico TA, Dilling TJ, Dobelbower M, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel SP, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M (2018). NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. J Natl Compr Canc Netw, 16(7), 807-821. (Read full article)
    20. Scagliotti GV, Shuster D, Orlov S, von Pawel J, Shepherd FA, Ross JS, Wang Q, Schwartz B, Akerley W (2017). Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study. J Thorac Oncol, 13(6), 849-854. (Read full article)
    21. Francis S, Orton A, Stoddard G, Tao R, Hitchcock YJ, Akerley W, Kokeny KE (2017). Sequencing of Postoperative Radiotherapy and Chemotherapy for Locally Advanced or Incompletely Resected Non-Small-Cell Lung Cancer. J Clin Oncol, 36(4), 333-341. (Read full article)
    22. Ou JY, Fowler B, Ding Q, Kirchhoff AC, Pappas L, Boucher K, Akerley W, Wu Y, Kaphingst K, Harding G, Kepka D (2018). A statewide investigation of geographic lung cancer incidence patterns and radon exposure in a low-smoking population. BMC Cancer, 18(1), 115. (Read full article)
    23. Gubens MA, Chuang JC, Akerley W, Langer CJ, Clment-Duchne C, San Pedro-Salcedo M, Colevas AD, Dragnev K, Socinski MA, Wakelee HA (2018). A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy. J Thorac Dis, 10(1), 219-227. (Read full article)
    24. Herde RF, Kokeny KE, Reddy CB, Akerley WL, Hu N, Boltax JP, Hitchcock YJ (2015). Primary Pulmonary Carcinoid Tumor: A Long-term Single Institution Experience. Am J Clin Oncol, 41(1), 24-29. (Read full article)
    25. Chalmers A, Jensen L, Akerley W (2017). Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report. Lung Cancer, 114, 68-69. (Read full article)
    26. Stinchcombe TE, Zhang Y, Vokes EE, Schiller JH, Bradley JD, Kelly K, Curran WJ Jr, Schild SE, Movsas B, Clamon G, Govindan R, Blumenschein GR, Socinski MA, Ready NE, Akerley WL, Cohen HJ, Pang HH, Wang X (2017). Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. J Clin Oncol, 35(25), 2885-2892. (Read full article)
    27. Akerley WL, Arnaud AM, Reddy B, Page RD (2017). Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer. Curr Med Res Opin, 33(6), 1091-1097. (Read full article)
    28. Akerley W (2017). Biomarker-Based Treatment Selection in Non-Small Cell Lung Cancer. J Natl Compr Canc Netw, 15(5S), 689-691. (Read full article)
    29. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, DAmico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M (2017). Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15(4), 504-535. (Read full article)
    30. Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, Pietanza MC, Wu YL, Zielinski C, Thomas M, Felip E, Gold K, Horn L, Aerts J, Nakagawa K, Lorigan P, Pieters A, Kong Sanchez T, Fairchild J, Spigel D (2016). Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. J Clin Oncol, 34(31), 3740-3748. (Read full article)
    31. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, DAmico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Swanson SJ, Stevenson J, Tauer K, Yang SC, Gregory K, Hughes M (2016). NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. J Natl Compr Canc Netw, 14(7), 825-36. (Read full article)
    32. Samadder NJ, Smith KR, Hanson H, Pimentel R, Wong J, Boucher K, Akerley W, Gilcrease G, Ulrich CM, Burt RW, Curtin K (2016). Familial Risk in Patients With Carcinoma of Unknown Primary. JAMA Oncol, 2(3), 340-6. (Read full article)
    33. Lara PN Jr, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL 3rd, Hirsch FR, Mack PC, Gandara DR (2016). SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. J Thorac Oncol, 11(3), 420-5. (Read full article)
    34. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, DAmico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M (2016). NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw, 14(3), 255-64. (Read full article)
    35. Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE 3rd, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ Jr, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart FM (2015). NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. J Natl Compr Canc Netw, 13(11), 1337-46. (Read full article)
    36. Carr SR, Akerley W, Hashibe M, Cannon-Albright LA (2015). Evidence for a genetical contribution to non-smoking-related lung cancer. Thorax, 70(11), 1033-9. (Read full article)
    37. Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, Orlov S, Santoro A, Spigel D, Hirsh V, Shepherd FA, Sequist LV, Sandler A, Ross JS, Wang Q, von Roemeling R, Shuster D, Schwartz B (2015). Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol, 33(24), 2667-74. (Read full article)
    38. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M, National comprehensive cancer network (2015). Non-Small Cell Lung Cancer, Version 6.2015. J Natl Compr Canc Netw, 13(5), 515-24. (Read full article)
    39. Oliver TG, Patel J, Akerley W (2015). Squamous non-small cell lung cancer as a distinct clinical entity. Am J Clin Oncol, 38(2), 220-6. (Read full article)
    40. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild S, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M (2014). Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw, 12(12), 1738-61. (Read full article)
    41. Berek JS, Edwards RP, Parker LP, DeMars LR, Herzog TJ, Lentz SS, Morris RT, Akerley WL, Holloway RW, Method MW, Plaxe SC, Walker JL, Friccius-Quecke H, Krasner CN (2014). Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int J Gynecol Cancer, 24(9), 1583-9. (Read full article)
    42. Nelson RE, Stenehjem D, Akerley W (2013). A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis. Lung Cancer, 82(3), 461-8. (Read full article)
    43. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M, National comprehensive cancer network (2013). Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw, 11(6), 645-53; quiz 653. (Read full article)
    44. Ettinger DS, Riely GJ, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M, National Comprehensive Cancer Network (2013). Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 11(5), 562-76. (Read full article)
    45. Akerley WL, Nelson RE, Cowie RH, Spinella DG, Hornberger J (2013). The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer. Curr Med Res Opin, 29(5), 517-25. (Read full article)
    46. Akerley W, Boucher K, Rich N, Egbert L, Harker G, Bylund J, Van Duren T, Reddy C (2013). A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation. Lung Cancer, 79(3), 307-11. (Read full article)
    47. Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan T, Koczywas M, Loo BW Jr, Merritt RE, Moran CA, Niell HB, OMalley J, Patel JD, Ready N, Rudin CM, Williams CC Jr, Gregory K, Hughes M, National Comprehensive Cancer Network (2013). Small cell lung cancer. J Natl Compr Canc Netw, 11(1), 78-98. (Read full article)
    48. Grossmann KF, Colman H, Akerley WA, Glantz M, Matsuoko Y, Beelen AP, Yu M, De Groot JF, Aiken RD, Olson JJ, Evans BA, Jensen RL (2012). Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme. J Neurooncol, 110(2), 257-64. (Read full article)
    49. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW Jr, Martins R, OMalley J, Osarogiagbon RU, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, Hughes M, Gregory KM, NCCN National Comprehensive Cancer Network (2012). Non-small cell lung cancer. J Natl Compr Canc Netw, 10(10), 1236-71. (Read full article)
    50. Margolin KA, Moon J, Flaherty LE, Lao CD, Akerley WL 3rd, Othus M, Sosman JA, Kirkwood JM, Sondak VK (2012). Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res, 18(4), 1129-37. (Read full article)
    51. Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, OMalley J, Osarogiagbon RU, Otterson GA, Patel JD, Schenck MP, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, National Comprehensive Cancer Network (2012). Malignant pleural mesothelioma. J Natl Compr Canc Netw, 10(1), 26-41. (Read full article)
    52. Poruk KE, Firpo MA, Boucher KM, Akerley WL, Neumayer LA, Sklow B, Scaife CL, Mulvihill SL (01/01/2012). Assessment of Serum Platelet Factor 4 as a Predictive Marker for VTE and as a Prognostic Biomarker in Pancreatic, Colorectal, Breast, and Lung Cancer. J Surg Res, 172(2), 242-243.
    53. Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow L, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan TM, Koczywas M, Moran CA, Niell HB, OMalley J, Patel JD, Ready N, Rudin CM, Williams CC Jr, National Comprehensive Cancer Network (2011). Small cell lung cancer. J Natl Compr Canc Netw, 9(10), 1086-113. (Read full article)
    54. Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE, Orlov S, Ramlau R, Arthur S, Gorbachevsky I, Schwartz B, Schiller JH (2011). Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol, 29(24), 3307-15. (Read full article)
    55. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, ODay SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group, Akerley WL (2011 June 30). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med, 2011 Jun(364(26):), 2507-16.
    56. Akerley W, Edwards S, Wilson R, Van Duren T, Akerley D, Tranter S, Sharry S (2011 June). Awareness of Radon - Associated Health Risks in Utah. 16(2011), 58-60.
    57. Tsimberidou AM, Akerley W, Schabel MC, Hong DS, Uehara C, Chhabra A, Warren T, Mather GG, Evans BA, Woodland DP, Swabb EA, Kurzrock R (2010). Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. Mol Cancer Ther, 9(12), 3410-9. (Read full article)
    58. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Govindan R, Grannis FW Jr, Jahan T, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, OMalley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, National Comprehensive Cancer Network (2010). Thymic malignancies. J Natl Compr Canc Netw, 8(11), 1302-15. (Read full article)
    59. Hodi FS, ODay SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebb C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 363(8), 711-23. (Read full article)
    60. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, OMalley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC, NCCN Non-Small Cell Lung Cancer Panel Members (2010). Non-small cell lung cancer. J Natl Compr Canc Netw, 8(7), 740-801. (Read full article)
    61. Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L, Akerley W (2009). Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol, 27(31), 5255-61. (Read full article)
    62. Stinchcombe TE, Hodgson L, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Niell HB, Atkins JN, Akerley W, Green MR, Vokes EE, Cancer and Leukemia Group B (2009). Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol, 4(9), 1117-25. (Read full article)
    63. Akerley W, Boucher KM, Bentz JS, Arbogast K, Walters T (2009). A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer. J Thorac Oncol, 4(2), 214-9. (Read full article)
    64. Ettinger DS, Akerley W, Bepler G, Chang A, cheney Rt, Chirieac LR, DAmico TA, Demmy TL et al (2008). Non-small cell lung cancer. J Natl Compr Canc Netw, 6(3), 228-269.
    65. Kalemkerian GP, Akerley W, Downey RJ, Ettinger DS, fossella F, Grecula JC et al (2008). Small cell lung cancer. J Natl Compr Canc Netw, 6(3), 294-314.
    66. Kalemkerian GP, Akerley W, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Johnson BE, Kessinger A, Koczywas M, Langer CJ, Martins R, Niell HB, Pan CC, Ramnath N, Ready N, Robert F, Williams CC Jr (2008). Small cell lung cancer. J Natl Compr Canc Netw, 6(3), 294-314. (Read full article)
    67. Ettinger DS, Akerley W, Bepler G, Chang A, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Feigenberg SJ, Figlin RA, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Patel JD, Robert F, Sugarbaker DJ, Wood DE (2008). Non-small cell lung cancer. J Natl Compr Canc Netw, 6(3), 228-69. (Read full article)
    68. Akerley W, McCoy J, Hesketh PJ, Goodwin JW, Bearden JD, Atkins JN, Chansky K, Crowley JJ, Gandara DR, SWOG (2007). Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119. J Thorac Oncol, 2(6), 526-30. (Read full article)
    69. Vokes EE, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, Atkins JN, Watson DM, Akerley W, Green MR (2007). Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol, 25(13), 1698-704. (Read full article)
    70. Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller JH (2006). Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol, 24(31), 5025-33. (Read full article)
    71. Akerley W, Safran H, Zaner K, Ready N, Mega T, Kennedy T (2006). Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer. Cancer, 107(5), 1050-4. (Read full article)
    72. Kim DW, Shyr Y, Chen H, Akerley W, Johnson DH, Choy H (2005). Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 63(4), 1029-36. (Read full article)
    73. Kim DW, Shyr Y, Shaktour B, Akerley W, Johnson DH, Choy H (2005). Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer. Lung Cancer, 50(2), 235-45. (Read full article)
    74. Akerley W, Herndon JE Jr, Lyss AP, Choy H, Turrisi A, Graziano S, Williams T, Zhang C, Vokes EE, Green MR (2005). Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534. Clin Lung Cancer, 7(1), 47-53. (Read full article)
    75. Socinski MA, Zhang C, Herndon JE 2nd, Dillman RO, Clamon G, Vokes E, Akerley W, Crawford J, Perry MC, Seagren SL, Green MR (2004). Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol, 15(7), 1033-41. (Read full article)
    76. Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis D, Ratain MJ, Green MR (2003). Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer, 97(10), 2480-6. (Read full article)
    77. Akerley W, Herndon J, Green M, et al (2003). Dose-Dense Weekly Paclitaxel and Pharmacologic Evaluation for Patients with Stage IIIB-IV Non-Small Cell Lung Cancer: A Phase II Trial of Cancer and Leukemia Group B (CALGB 9731/9765). Cancer, 97, 2480-6.
    78. Akerley W, Rathore R, Ready N, Leone L, Sikov W, Safran H, Kennedy T (2002). A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma. Cancer, 95(9), 2000-5. (Read full article)
    79. Akerley W, Butera J, Wehbe T, Noto R, Stein B, Safran H, Cummings F, Sambandam S, Maynard J, Di Rienzo G, Leone L (2002). A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer, 94(6), 1654-60. (Read full article)
    80. Blackstock AW, Herndon JE 2nd, Paskett ED, Perry MC, Graziano SL, Muscato JJ, Kosty MP, Akerley WL, Holland J, Fleishman S, Green MR (2002). Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Natl Cancer Inst, 94(4), 284-90. (Read full article)
    81. Blackstock A, Herndon J, Paskett E, Perry M, Graziano S, Muscato, Kosty M, Akerley W, Holland J, Fleishman S, Green M (2002). Outcomes Among African-American and Non African-American Patients with Advanced Non-Small Cell Lung Cancer: A Report from the CALGB. J Natl Cancer Inst, 94(4), 284-90.
    82. Akerley W, Butera J, Wehbe T, Noto R, Stein B, Safran H, Cummings F, Sambandam S, Maynard J, Di Rienzo G, Leone L (2002). A Multiinstitutional, Concurrent Chemoradiation Trial of Strontium-89, Estramustine, and Vinblastine for Hormone Refractory Prostate Carcinoma Involving Bone. Cancer, 94(6), 1654-1660.
    83. Makarovskiy A, Siryaporn E, Hixon D, Akerley W (2002). Survival of Docetaxel-resistant Prostate Cancer Cells Depends on Phenotype Alterations and Continuity of Drug Exposure. Cell Mol Life Sci, 59, 1198-1211.
    84. Akerley W, Rathore R, Ready N, Leone L, Sikov W, Safran H, Kennedy T (2002). A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma. Cancer, 95(9), 2000-5.
    85. Akerley W (2001). Recent developments in weekly paclitaxel therapy in lung cancer. Curr Oncol Rep, 3(2), 165-9. (Read full article)
    86. Gurevich I, Akerley W (2001). Treatment of the Jaundiced Patient with Breast Carcinoma. Cancer, 91(4), 660-663.
    87. Akerley W (2001). Recent Development in Weekly Paclitaxel Therapy of Lung Cancer. Curr Oncol Rep, 3(2), 165-169.
    88. Wanebo H, Chougule P, Ready N, Safran H, Akerley W, Koness R, McRae R, Nigri P, Leone L, Kennedy T, Webber B (2001). Surgical Resection is Necessary to Maximize Tumor Control In Function Preserving, Aggressive Chemoradiation Protocols for Advanced Squamous Cancer of the Head and Neck (Stage III and IV). Ann Surg Oncol, 8, 644-50.
    89. Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ, Vogelzang NJ (2001). Phase II Study of Docetaxel, Estramustine, and Low-dose Hydrocortisone in Men with Hormone-refractory Prostate Cancer: a final report of CALGB 9780. J Clin Oncol, 19(9), 2509-16.
    90. Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, Fulton D, Gilbert M, Heros D, Rogers L, ODay SJ, Akerley W, Allen J, Baidas S, Gertler SZ, Greenberg HS, LaFollette S, Lesser G, Mason W, Recht L, Wong E, Chamberlain MC, Cohn A, Glantz MJ, Gutheil JC, Maria B, Moots P, New P, Russell C, Shapiro W, Swinnen L, Howell SB (2001). Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer, 84(2), 157-63. (Read full article)
    91. King TC, Akerley W, Fan AC, Moore T, Mangray S, Hsiu Chen M, Safran H (2000). p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma. Cancer, 89(4), 769-73. (Read full article)
    92. Akerley W 3rd (2000). Paclitaxel in advanced non-small cell lung cancer : an alternative high-dose weekly schedule. Chest, 117(4 Suppl 1), 152S-155S. (Read full article)
    93. Akerley W (2000). Secondary Leukemia: Twice is a Coincidence? Cancer, 88(3), 497-9.
    94. Dupuy D, Zagoria R, Akerley W, Mayo-Smith W, Kavanagh P, Safran H (2000). Percutaneous Radiofrequency Ablation of Malignancies in the Lung. Am J Roentgenol Radium Ther Nucl Med, 174(1), 57-9.
    95. Akerley W (2000). Paclitaxel in Advanced Non-small Cell Lung Cancer: An Alternative High-dose Weekly Schedule. Chest, 117:4 (suppl 1), 152-5.
    96. King T, Akerley W, Fan A, Walsh K, Mangray S, Chen M, Safran H (2000). P53 Mutations Do Not Predict Response to Paclitaxel for Metastatic Non-Small Cell Lung Cancer. Cancer, 89(4), 769-73.
    97. Dupuy DE, Zagoria RJ, Akerley W, Mayo-Smith WW, Kavanagh PV, Safran H (2000). Percutaneous radiofrequency ablation of malignancies in the lung. AJR Am J Roentgenol, 174(1), 57-9. (Read full article)
    98. Akerley W, Choy H (1999). Single-agent paclitaxel and radiation for non-small cell lung cancer. Semin Radiat Oncol, 9(2 Suppl 1), 85-9. (Read full article)
    99. Wanebo HJ, Chougule P, Ready N, Koness RJ, Akerley W, McRae R, Nigri P, Leone L, Webber B, Safran H (1999). Preoperative paclitaxel, carboplatin, and radiation therapy in advanced head and neck cancer (stage III and IV). Semin Radiat Oncol, 9(2 Suppl 1), 77-84. (Read full article)
    100. Chougule PB, Akhtar MS, Akerley W, Ready N, Safran H, McRae R, Nigri P, Bellino J, Koness J, Radie-Keane K, Wanebo H (1999). Chemoradiotherapy for advanced inoperable head and neck cancer: A phase II study. Semin Radiat Oncol, 9(2 Suppl 1), 58-63. (Read full article)
    101. Chougule P, Akhtar M, Akerley W, Ready N, Safran H, McRae R, Nigri P, Bellino J, Koness R, Radie-Kane K, and Wanebo H (1999). Chemoradiotherapy for Advanced Inoperable Head and Neck Cancer: A Phase II Study. Semin Radiat Oncol, 9(2) suppl 1, 58-63.
    102. Akerley W and Choy H (1999). Single Agent Paclitaxel and Radiation for Non-Small Cell Lung Cancer. Semin Radiat Oncol, 9(2) suppl 1, 85-89.
    103. Wanebo H, Chougule P, Ready N, Koness R, Akerley W, McRae R, Nigri P, Leone L, Webber B, Safran H (1999). Preoperative Paclitaxel, Carboplatin and Radiation Therapy in Advanced Head and Neck Cancer. Semin Radiat Oncol, 9(2) suppl 1, 77-84.
    104. Glantz M, Kim L, Choy H, Akerley W (1999). Concurrent Chemotherapy and Radiotherapy in Patients with Brain Tumors. Oncology, 13(10) suppl 5, 78-82.
    105. Choy H, Akerley W, Safran H, Graziano S, Chung C, Williams T, Cole B, Kennedy T (1998). Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol, 16(10), 3316-22. (Read full article)
    106. Choy H, Safran H, Akerley W, Graziano SL, Bogart JA, Cole BF (1998). Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res, 4(8), 1931-6. (Read full article)
    107. Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, Hochberg F, Calabresi P, Egorin MJ (1998). High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol, 16(4), 1561-7. (Read full article)
    108. Recht LD, Glantz MJ, Meitner P, Glantz L, Akerley W, Wahlberg L, Saris S, Cole BF (1998). Unexpected in vitro chemosensitivity of malignant gliomas to 4-hydroxyperoxycyclophosphamide (4-HC). J Neurooncol, 36(3), 201-8. (Read full article)
    109. Akerley W (1998). Oncology: Combined Modalilty Therapy in Non-Small Cell Lung Cancer. 2(3), 14-15.
    110. Clamon G, Herndon J, Akerley W, Green M (1998). Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer: a phase II trial of Cancer and Leukemia Group B. Lung Cancer, 19(1), 25-9. (Read full article)
    111. Akerley W, Glantz M, Choy H, Rege V, Sambandam S, Joseph P, Yee L, Rodrigues B, Wingate P, Leone L (1998). Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol, 16(1), 153-8. (Read full article)
    112. Chougule P, Wanebo H, Akerley W, McRae R, Nigri P, Leone L, Safran H, Ready N, Koness RJ, Radie-Keane K, Cole B (1997). Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: a phase II study--preliminary results. Semin Oncol, 24(6 Suppl 19), S19-57-S19-61. (Read full article)
    113. Wanebo HJ, Chougule P, Akerley WL 3rd, Koness RJ, McRae R, Nigri P, Leone L, Ready N, Safran H, Webber B, Cole B (1997). Preoperative chemoradiation coupled with aggressive resection as needed ensures near total control in advanced head and neck cancer. Am J Surg, 174(5), 518-22. (Read full article)
    114. Akerley W, Sikov WM, Cummings F, Safran H, Strenger R, Marchant D (1997). Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report. Semin Oncol, 24(5 Suppl 17), S17-87-S17-90. (Read full article)
    115. Akerley W, Choy H, Safran H, Sikov W, Rege V, Sambandam S, Wittels E (1997). Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial. Semin Oncol, 24(4 Suppl 12), S12-10-S12-13. (Read full article)
    116. Safran H, King TP, Choy H, Hesketh PJ, Wolf B, Altenhein E, Sikov W, Rosmarin A, Akerley W, Radie-Keane K, Cicchetti G, Lopez F, Bland K, Wanebo HJ (1997). Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study. J Clin Oncol, 15(3), 901-7. (Read full article)
    117. Choy H, Akerley W, Safran H, Graziano S (1997). Concurrent Weekly Paclitaxel and Radiation Therapy for Locally Advanced NSCLC. Lung Cancer, 18(S2), 152.
    118. Choy H, King T, Akerley W, Safran H (1997). Paclitaxel and Concurrent Radiation for Lung, Pancreatic and Gastric Carcinomas: Significance of p53 Gene Mutations for Treatment Response. Semin Radiat Oncol, 7(3), s77-81.
    119. Choy H, Akerley W, Safran H, Clark J, Rege V, Papa A, Glantz M, Puthawala Y, Soderberg C, Leone L (1997). Phase I Trial of Outpatient Weekly Paclitaxel and Concurrent Radiation Therapy for Advanced Non-Small Cell Lung Cancer. 2(1), 167-71.
    120. Choy H, Akerley W, Devore R (1997). Paclitaxel in Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. 13(4), 17-24.
    121. Makarovskiy A, Ackerley W, Wojcik W, Halpert G, Stein B, Carreiro M, Hixson D (1997). Application of Immunomagnetic Beads in Combination with RT-PCR for the Detection of Circulating Prostate Cancer Cells. J Clin Lab Anal, 11, 346-50.
    122. Glantz MJ, Choy H, Akerley W, Kearns CM, Egorin MJ, Rhodes CH, Cole BF (1996). Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response. Semin Oncol, 23(6 Suppl 16), 128-35. (Read full article)
    123. Choy H, Akerley W, Safran H, Graziano S, Chung C (1996). Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-small cell lung cancer. Semin Oncol, 23(6 Suppl 16), 117-9. (Read full article)
    124. Akerley W (1996). Phase I/II trial of weekly paclitaxel in patients with advanced lung cancer. Semin Oncol, 23(6 Suppl 16), 55-8. (Read full article)
    125. Akerley W 3rd, Glantz M, Choy H (1996). Preliminary results of a phase I study of weekly paclitaxel infusion in patients with non-small cell lung cancer. Semin Oncol, 23(5 Suppl 12), 14-8. (Read full article)
    126. Choy H, Akerley W, Glantz M, Safran H, Graziano S, Chung C (1996). Concurrent Paclitaxel and Radiation Therapy for Solid Tumors. Cancer Control, 3(4), 310-318. (Read full article)
    127. Glantz MJ, Cole BF, Friedberg MH, Lathi E, Choy H, Furie K, Akerley W, Wahlberg L, Lekos A, Louis S (1996). A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology, 46(4), 985-91. (Read full article)
    128. Glantz M, Choy H, Akerley W, Kearns C, Egorin M, Rhodes H, Cole B (1996). Weekly Paclitaxel With and Without Concurrent Radiation Therapy: Toxicity, Pharmacokinetics and Response. Semin Oncol, 23(6) Suppl 16, 128-135.
    129. Akerley W, Glantz M, Choy H (1996). Phase I Study of Weekly Outpatient Paclitaxel in Advanced and Metastatic Non-small Cell Lung Cancer. Semin Oncol, 23(5), Suppl 12, 14-18.
    130. Clark J, Sikov W, Cummings F, Browne M, Akerley W, Wanebo H, Weitberg A, Kennedy T, Cole B, Bigley J, Beitz J, Darnowski J (1996). Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol, 122(9), 554-8. (Read full article)
    131. Glantz MJ, Choy H, Kearns CM, Akerley W, Egorin MJ (1995). Weekly, outpatient paclitaxel and concurrent cranial irradiation in adults with brain tumors: preliminary results and promising directions. Semin Oncol, 22(5 Suppl 12), 26-32. (Read full article)
    132. Glantz MJ, Hall WA, Cole BF, Chozick BS, Shannon CM, Wahlberg L, Akerley W, Marin L, Choy H (1995). Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer, 75(12), 2919-31. (Read full article)
    133. Akerley W, Choy H (1995). Concurrent paclitaxel and thoracic radiation for advanced non-small cell lung cancer. Lung Cancer, 12 Suppl 2, S107-15. (Read full article)
    134. Choy H, Akerley W, Safran H, Clark J, Rege V, Papa A, Glantz M, Puthawala Y, Soderberg C, Leone L (1994). Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol, 12(12), 2682-6. (Read full article)
    135. Miller ME, Dores GM, Thorpe SL, Akerley WL (1994). Paradoxical influence of estrogenic hormones on platelet-endothelial cell interactions. Thromb Res, 74(6), 577-94. (Read full article)
    136. Akerley WL 3rd, Moritz TE, Ryan LS, Henderson WG, Zacharski LR (1993). Racial comparison of outcomes of male Department of Veterans Affairs patients with lung and colon cancer. Arch Intern Med, 153(14), 1681-8. (Read full article)
    137. Posner M, Martin A, Slapak CA, Clark JW, Cummings FJ, Robert NJ, Sikov W, Akerley W (1992). A phase II trial of continuous infusion cisplatin and 5-fluorouracil with oral calcium leucovorin in colorectal carcinoma. Am J Clin Oncol, 15(3), 239-41. (Read full article)
    138. Akerley WL 3rd, Guyre PM, Davis BH (1991). Neutrophil activation through high-affinity Fc gamma receptor using a monomeric antibody with unique properties. Blood, 77(3), 607-15. (Read full article)
    139. Grunberg SM, Ehler E, McDermed JE, Akerley WL (1988). Oral metoclopramide with or without diphenhydramine: potential for prevention of late nausea and vomiting induced by cisplatin. J Natl Cancer Inst, 80(11), 864-8. (Read full article)
    140. Grunberg SM, Akerley WL, Krailo MD, Johnson KB, Baker CR, Cariffe PA (1986). Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis. Cancer Invest, 4(5), 379-85. (Read full article)

    Review

    1. Sandler A, Hirsh V, Reck M, von Pawel J, Akerley W, Johnson DH (2012). An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases. [Review]. Lung Cancer, 78(1), 1-7. (Read full article)

    Editorial

    1. Chalmers AW, Patel SB, Akerley W (2018). Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care? J Thorac Dis, 10(3), 1198-1200. (Read full article)

    Letter

    1. Chalmers A, Akerley W (2017). Retrospective, Multi-Institutional Analysis of Sequential Treatment of Brain Metastases in Treatment-Naïve, Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer Should Not Define the Standard of Practice. [Letter to the editor]. J Clin Oncol, 35(20), 2340. (Read full article)

    Other

    1. Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples AR (2021). Impact of the COVID-19 pandemic on exercise habits among cancer patients. United States. (Read full article)

  • News & Podcasts

    Huntsman Cancer Institute News

    Podcasts